Antinuclear Antibody Test Market - Forecast(2025 - 2031)
Overview
Antinuclear Antibody Test Market is projected to reach revenue of $4980.4 Million by 2030, and is estimated to grow at a CAGR of 11.60% during the forecast period 2024-2030. The Antinuclear Antibody test market size, in 2018, is $1.04 billion. Antinuclear Antibody tests are done to evaluate an individual for autoimmune disorders. Antinuclear antibodies (ANA) are produced as an immune response to foreign bodies. Sometimes these ANAs attack the cells within the body which leads to autoimmune disorders such as lupus, scleroderma, and rheumatoid arthritis. These ANAs are also called autoantibodies.
Key Takeaways
- The market is estimated to grow at a CAGR of 12.4%. With rising prevalence of autoimmune disorders, antinuclear antibody testing has also risen.
- Rising awareness and availability of range of diagnostic tools contribute to the growth in this market. Advances in technology and increasing investment in healthcare is also driving the market.
Test Product - Segment Analysis
Reagent assay kits occupy the largest share in the antinuclear antibody test market. Laboratories commonly use reagent assay kits to test for antibodies. These reagent assays are popularly used as they are convenient, efficient, and accurate.
Test Technique - Segment Analysis
As per the technique of antinuclear antibody test, ELISA (enzyme linked immunosorbent assay) has the major share. This is due to the frequent use of this test for autoimmune disorder tests. It detects and measures the antibodies from blood and hence is convenient. ELISA is commonly used for detecting diseases such as HIV, Lyme disease, and others.
Test Application - Segment Analysis
Rheumatoid arthritis segment is estimated to have the largest share by test application and is growing at a CAGR of 9.70%. This disease is highly prevalent and affects mostly those within the age group of 35-50. Women are more likely to get this disease as compared to men.
Test End-Use - Segment Analysis
The hospital segment is said to have the highest share by test end-use. Hospitals are most frequented by patients and thus a large number of tests are being conducted here compared to clinics and laboratories.
Geography - Segment Analysis
North America accounts for largest Antinuclear Antibody test market share with 35% in 2018. According to the American Autoimmune Related Diseases Association, 50 million Americans have Autoimmune Diseases. This huge number is said to contribute to growth in the antinuclear antibody test market as larger number of tests will be done by these patients.
Drivers – Antinuclear Antibody Test Market
- Rising prevalence of autoimmune diseases globally
Antibodies protect body by strengthening the immune system. However, if a test detects antinuclear antibodies in the body of an individual, it could mean that the person has an autoimmune disorder. An antinuclear antibodies test is used to help diagnose autoimmune disorders. As per the National Institutes of Health, about 23.5 million Americans are affected by autoimmune diseases. Also, the Connect Immune Research reports that costs for just 3 autoimmune diseases, namely, type 1 diabetes, rheumatoid arthritis and multiple sclerosis, add up to more than £13 billion per year in UK. Rising incidence of autoimmune disease have led to growth of the antinuclear antibody test market.
- Advances in technology and research developments
Discovery of biomarkers and laboratory automation is also said to drive the market. Biomarkers are useful in identifying the diseases type, progression and more. Thus they are useful in developing tests for the autoimmune diseases. Also with rising autoimmune diseases, a number of samples are being used in their tests. Thus laboratory automation is also crucial in handling these samples with accuracy and efficiency.
Antinuclear Antibody Test Industry Outlook
Research & development along with strategic alliances are some of the key strategies adopted by players in the Antinuclear Antibody test market. Antinuclear Antibody Test Market top 10 companies are Alere Inc., Bio-Rad Laboratories, Inc., ERBA Diagnostics, Inc., Trinity Biotech plc, Thermo Fisher Scientific, Inc., Antibodies, Inc., Inova Diagnostics, Zeus Scientific, Inc., F. Hoffmann-La Roche Ltd., and Becton Dickinson and Company.
Antinuclear Antibody Test Market Research Scope:
The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Antinuclear Antibody Test Market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats.